ArticleBMC research notes2026
Ranolazine attenuates diabetic cardiomyopathy in rats by suppressing AGE-RAGE axis and oxidative stress.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Different Doses of Ranolazine on SIRT1, APELA, and APL13 in a Rat MCAO Model.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveDiabetes mellitus is a significant global health issue. Chronic hyperglycemia leads to the formation of advanced glycation end products (AGEs) and oxidative stress, both of which contribute to diabetic complications, including cardiovascular diseases. This study explores the effects of ranolazine, an antianginal agent with known metabolic benefits, on AGEs, their receptor (RAGE), and oxidative stress in type 2 diabetic rats.
resultsRanolazine treatment did not significantly reduce serum glucose levels in diabetic rats but significantly decreased malondialdehyde (MDA) levels and increased glutathione peroxidase (GPx) activity. Serum levels of pentosidine and carboxymethyl-lysine (CML) were also significantly lowered in ranolazine-treated diabetic rats. Furthermore, ranolazine downregulated RAGE expression in cardiac tissue, suggesting a reduction in AGE-mediated damage. In vitro assays showed that ranolazine did not directly inhibit albumin glycation, implying that its effects on AGEs and RAGE are likely mediated through improved metabolic and antioxidative mechanisms rather than direct interference with glycation. These findings highlight ranolazine’s potential to mitigate AGE-related damage and oxidative stress in diabetic cardiomyopathy, independent of glucose-lowering effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.